Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 35-43

  Huizinga, T W J ^a   Conaghan, Philip G ^b   Martin Mola, Emilio ^c   Schett, Georg ^d   Amital, Howard ^e   Xavier, Ricardo M ^f   Troum, Orrin ^g   Aassi, Maher ^h   Bernasconi, Corrado ^h   Dougados, Maxime ⁱ  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e SHEBA MEDICAL CENTER   (Israel)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL CANDIDIASIS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILIARY TUBERCULOSIS; NEUTROPHIL COUNT; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; THROMBOCYTE COUNT; TREATMENT RESPONSE; AGED; ARTHRITIS, RHEUMATOID; BLOOD; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FOOT; HAND JOINT; INDUCTION CHEMOTHERAPY; LONGITUDINAL STUDY; MAINTENANCE CHEMOTHERAPY; RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOOT JOINTS; HAND JOINTS; HUMANS; INDUCTION CHEMOTHERAPY; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84917726540     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205752     Document Type: Article

References (22)

1. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
3. Allaart CF, Lems WF, Huizinga TW. The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 2013;31(4 Suppl 78):S14-18.
4. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: When and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636-42.
5. Quinn MA, Conaghan PG, O' Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained bene fit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
6. van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: Subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
7. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
8. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73:803-9.
9. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: Smallest detectable difference or change. Ann Rheum Dis 2005;64:179-82.
10. Lee SJ, Chang H, Yazici Y, et al. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a united states observational cohort study. J Rheumatol 2009;36:1611-17.
11. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: Even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the german biologics register. Arthritis Res Ther 2006;8:R66.
12. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the french registries. Rheumatology (Oxford) 2011;50:222-9.
13. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the british society for rheumatology biologics register. Ann Rheum Dis 2011;70:583-9.
14. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
15. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66: 1162-7.
16. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-19.
17. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. Lancet 2013;381:918-29.
18. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
19. Tanaka Y, Hirata S, Saleem B, et al. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013;31(4 Suppl 78):S22-7.
20. Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: The CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2014. Published Online First: 15 Jan 2014. doi:10.1136/annrheumdis-2013-204632
21. Bykerk VP, Ostor AJ, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012;71:1950-4.
22. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken) 2013;65:362-71.